EFFECTOR Therapeutics Performance
| EFTRWDelisted Stock | USD 0 0.00 0.00% |
The firm shows a Beta (market volatility) of 3.1, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, EFFECTOR Therapeutics will likely underperform. EFFECTOR Therapeutics at this time shows a risk of 0.0%. Please confirm EFFECTOR Therapeutics total risk alpha, as well as the relationship between the downside variance and day median price , to decide if EFFECTOR Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days EFFECTOR Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, EFFECTOR Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 8.7 M |
EFFECTOR |
EFFECTOR Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.10 in EFFECTOR Therapeutics on August 29, 2024 and sell it today you would earn a total of 0.00 from holding EFFECTOR Therapeutics or generate 0.0% return on investment over 90 days. EFFECTOR Therapeutics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than EFFECTOR, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
EFFECTOR Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EFFECTOR Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as EFFECTOR Therapeutics, and traders can use it to determine the average amount a EFFECTOR Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EFTRW |
Based on monthly moving average EFFECTOR Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EFFECTOR Therapeutics by adding EFFECTOR Therapeutics to a well-diversified portfolio.
EFFECTOR Therapeutics Fundamentals Growth
EFFECTOR Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of EFFECTOR Therapeutics, and EFFECTOR Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EFFECTOR Pink Sheet performance.
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| EBITDA | (33.73 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Total Asset | 20.54 M | |||
| Retained Earnings | (179.38 M) | |||
About EFFECTOR Therapeutics Performance
Evaluating EFFECTOR Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if EFFECTOR Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if EFFECTOR Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about EFFECTOR Therapeutics performance evaluation
Checking the ongoing alerts about EFFECTOR Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for EFFECTOR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EFFECTOR Therapeutics is not yet fully synchronised with the market data | |
| EFFECTOR Therapeutics has some characteristics of a very speculative penny stock | |
| EFFECTOR Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| EFFECTOR Therapeutics generates negative cash flow from operations |
- Analyzing EFFECTOR Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EFFECTOR Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining EFFECTOR Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EFFECTOR Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of EFFECTOR Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EFFECTOR Therapeutics' pink sheet. These opinions can provide insight into EFFECTOR Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |